{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.7","upperLimit":"80.1","value":"67.9"},{"groupId":"OG001","lowerLimit":"72.6","upperLimit":"89.8","value":"82.4"},{"groupId":"OG002","lowerLimit":"27.5","upperLimit":"66.1","value":"46.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"28"}],"units":"Participants"}],"description":"Overall CR rate was defined as the percentage of participants who met at least one of the following: negative cystoscopy and negative (including atypical) centrally read urine cytology, or positive cystoscopy with biopsy-proven benign or low-grade non-muscle invasive bladder cancer (NMIBC) and negative (including atypical) centrally read cytology at any time point.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with CIS with or without papillary disease, received TAR-200 intravesically every 3 weeks (Q3W) from Week 0 for the first 24 weeks, followed by every 12 weeks (Q12W) dosing through Week 99 in combination with cetrelimab 360 milligrams (mg) intravenously (IV) Q3W from Week 0 through Week 78. TAR-200 was inserted intravesically via the urinary placement catheter (UPC).","id":"OG000","title":"Cohort 1: TAR-200 + Cetrelimab (CIS With or Without Papillary Disease)"},{"description":"Participants with CIS with or without papillary disease, received TAR-200 intravesically Q3W from Week 0 for the first 24 weeks, followed by Q12W dosing through Week 99. TAR-200 was inserted intravesically via UPC.","id":"OG001","title":"Cohort 2: TAR-200 Monotherapy (CIS With or Without Papillary Disease)"},{"description":"Participants with CIS with or without papillary disease, received cetrelimab 360 mg IV Q3W from Week 0 through Week 78.","id":"OG002","title":"Cohort 3: Cetrelimab IV Monotherapy (CIS With or Without Papillary Disease)"}],"paramType":"NUMBER","populationDescription":"Full analysis set (FAS) included all enrolled participants who received at least 1 dose of study treatment. Here \"N\" (overall number of participants analyzed) signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From date of first dose up to clinical cut-off date 3rd July 2025 (up to 50 months)","title":"Cohorts 1, 2, and 3: Overall Complete Response (CR) Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}